A Phase 1 interventional study of BIBR 953 ZW IV and BIBR 1048 MS tablet in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-23.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Two substudies to assess (1) the tolerability of BIBR 953 ZW intravenous infusion at 0.1, 1 and 5 mg BIBR 953 ZW and (2) the absolute bioavailability of 100mg BIBR 1048 administered as 'acid free' tablet formulation (TF1) and (3) the bioavailability of the 100 mg tablet of BIBR 1048 relative to the tartaric acid solution of 100 mg dose strength and (4) the absolute bioavailability of the 100 mg tartaric acid solution of BIBR 1048 MS.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BIBR 953 ZW IV
Drug: BIBR 1048 MS oral solution
Drug: BIBR 1048 MS tablet
Drug: BIBR 953 ZW IV Placebo
AUC0-inf (Area under the plasma concentration-time curve extrapolated to infinity)
Time frame: up to 48 hours after drug administration
AUC0-tf (Area under the plasma concentration-time curve up to the last quantifiable plasma concentration)
Time frame: up to 48 hours after drug administration
Cmax (Maximum plasma concentration after oral administration)
Time frame: up to 48 hours after drug administration
Cumulative urinary excretion of BIBR 953 ZW administered intravenously
Time frame: up to 48 hours after drug administration
changes in activated partial thromboplastin time (aPTT )
Time frame: up to 48 hours after drug administration
changes in prothrombin time (PT)
Time frame: up to 48 hours after drug administration
C29 (Plasma concentration of BIBR 953 ZW at 29 minutes after the start of the 30 min. infusion)
Time frame: 29 minutes after start of infusion
t1/2 (terminal half-life)
Time frame: up to 48 hours after infusion
CLtot (total clearance of drug from plasma)
Time frame: up to 48 hours after infusion
CLren (renal clearance from plasma)
Time frame: up to 48 hours after infusion
MRTdisp (Mean time of residence of drug molecules in the body after intravascular administration)
Time frame: up to 48 hours after infusion
Vss (apparent volume of distribution at steady state)
Time frame: up to 48 hours after infusion
Vz (Apparent volume of distribution during the terminal elimination phase)
Time frame: up to 48 hours after infusion
MRTtot (total mean residence time)
Time frame: up to 48 hours after oral administration
CLtot/F (total clearance after oral administration)
Time frame: up to 48 hours after oral administration
tmax (time to reach the peak plasma concentration)
Time frame: up to 48 hours after oral administration
Vz/F (apparent volume of distribution of the terminal elimination phase after oral administration)
Time frame: up to 48 hours after oral administration
changes in Ecarin clotting time (ECT)
Time frame: up to 48 hours after drug administration
changes in thrombin time (TT)
Time frame: up to 48 hours after drug administration
changes in vital signs (systolic and diastolic blood pressure, pulse rate)
Time frame: up to 1 month
changes in electrocardiogram
Time frame: up to 1 month
occurrence of adverse events
Time frame: up to 1 month
No study locations are listed for this record.
The record gives a start of Jan 2001 and a primary completion of Mar 2001. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran